This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

phentolamine mesylate (OraVerse®)

Reference No. 816

Publication date:

Appraisal information

phentolamine mesylate (OraVerse®) 400 micrograms/1.7 ml solution for injection

Company: Septodont Ltd
BNF category: Anaesthesia
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 25/04/2012

Current Progress

Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, phentolamine mesylate (OraVerse®) cannot be endorsed for use within NHS Wales for reversal of soft tissue anaesthesia (lip and tongue), and the associated functional deficits, resulting from an intraoral submucosal injection of a local anaesthetic containing a catecholamine vasoconstrictor, such as epinephrine, following a routine dental procedure such as teeth cleaning, scaling and planing, cavity filling or crowns.
Statement of Advice (SOA)